Skip to content
10-K

Annual Report

ENTRADA THERAPEUTICS, INC. TRDA

0001689375-25-000011

← back to feed
Filed
Feb 27, 2025 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding FY 2024 · Feb 20, 2025 37.59M sh
Shares Diluted FY 2024 · Dec 31, 2023 33.05M sh
Capex FY 2024 · Dec 31, 2023 $5.61M
Operating Cash Flow FY 2024 · Dec 31, 2023 $139.8M
Cash And Equivalents FY 2024 · Dec 31, 2023 $67.6M
Current Liabilities FY 2024 · Dec 31, 2023 $158.8M
Total Liabilities FY 2024 · Dec 31, 2023 $226.83M
Current Assets FY 2024 · Dec 31, 2023 $369.77M
Total Assets FY 2024 · Dec 31, 2023 $469.19M
Eps Diluted FY 2024 · Dec 31, 2023 −$0.20
Eps Basic FY 2024 · Dec 31, 2023 −$0.20
Sga Expense FY 2024 · Dec 31, 2023 $32.29M
Rd Expense FY 2024 · Dec 31, 2023 $99.88M
Net Income FY 2024 · Dec 31, 2023 −$6.69M
Operating Income FY 2024 · Dec 31, 2023 −$3.16M
Revenue FY 2024 · Dec 31, 2023 $129.01M
Stockholders Equity FY 2024 · Dec 31, 2022 $212.55M